We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
-13.83%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$6.51B
AUM Growth
-$1.01B
Cap. Flow
+$139M
Cap. Flow %
2.14%
Top 10 Hldgs %
20.49%
Holding
891
New
87
Increased
331
Reduced
275
Closed
84

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$32.8M
2
EC icon
Ecopetrol
EC
+$29.1M
3
AET
Aetna Inc
AET
+$20.2M
4
XOM icon
ExxonMobil
XOM
+$19.6M
5
AMGN icon
Amgen
AMGN
+$19.2M

Sector Composition

Rank Sector Weight
1 Healthcare 35.31%
2 Technology 15.37%
3 Financials 11.61%
4 Consumer Discretionary 8.19%
5 Communication Services 7.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CXO
201
DELISTED
CONCHO RESOURCES INC.
CXO
$7.67M 0.12%
74,658
+5,003
+7% +$664K
CHTR icon
202
Charter Communications
CHTR
$14.7B
$7.65M 0.12%
26,850
-759
-3% -$238K
APA icon
203
APA Corp
APA
$12.8B
$7.64M 0.12%
291,261
-2,775
-0.9% -$102K
FLIR
204
DELISTED
FLIR Systems, Inc. (DE) Common Stock
FLIR
$7.6M 0.12%
174,493
+80,629
+86% +$3.96M
GM icon
205
General Motors
GM
$74.7B
$7.59M 0.12%
227,022
+136,483
+151% +$4.71M
VLO icon
206
Valero Energy
VLO
$89.8B
$7.54M 0.12%
100,613
-16,981
-14% -$1.49M
STI
207
DELISTED
SunTrust Banks, Inc.
STI
$7.48M 0.11%
148,238
-48,849
-25% -$2.92M
LECO icon
208
Lincoln Electric
LECO
$13.8B
$7.47M 0.11%
94,778
+46,119
+95% +$3.83M
GS icon
209
Goldman Sachs
GS
$313B
$7.47M 0.11%
44,706
-18,652
-29% -$3.76M
CTMX icon
210
CytomX Therapeutics
CTMX
$705M
$7.41M 0.11%
490,988
+98,261
+25% +$1.46M
RGA icon
211
Reinsurance Group of America
RGA
$15.7B
$7.41M 0.11%
52,870
-1,990
-4% -$282K
SPR
212
DELISTED
Spirit AeroSystems
SPR
$7.41M 0.11%
102,855
+46,842
+84% +$3.8M
ARWR icon
213
Arrowhead Research
ARWR
$12.1B
$7.38M 0.11%
594,000
+80,000
+16% +$1.09M
AWK icon
214
American Water Works
AWK
$26.3B
$7.37M 0.11%
81,217
-11,058
-12% -$1.01M
WUBA
215
DELISTED
58.com Inc
WUBA
$7.32M 0.11%
135,000
-142,500
-51% -$8.69M
ITCI
216
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$7.27M 0.11%
638,000
+90,000
+16% +$1.45M
TBPH icon
217
Theravance Biopharma
TBPH
$874M
$7.16M 0.11%
279,700
+25,000
+10% +$675K
BBWI icon
218
Bath & Body Works
BBWI
$4.01B
$7.12M 0.11%
342,901
-240,759
-41% -$6.07M
PBYI icon
219
Puma Biotechnology
PBYI
$406M
$7.04M 0.11%
345,737
+29,537
+9% +$886K
APLS
220
DELISTED
Apellis Pharmaceuticals
APLS
$6.96M 0.11%
527,700
+12,000
+2% +$184K
AMT icon
221
American Tower
AMT
$77.7B
$6.93M 0.11%
43,782
+1,186
+3% +$185K
MGNX icon
222
MacroGenics
MGNX
$235M
$6.9M 0.11%
542,987
+186,387
+52% +$3.13M
SEND
223
DELISTED
SendGrid, Inc.
SEND
$6.87M 0.11%
+159,219
New +$6.13M
PPLI
224
People Inc
PPLI
$3.1B
$6.85M 0.11%
209,436
+88,184
+73% +$2.96M
IDTI
225
DELISTED
Integrated Device Technology I
IDTI
$6.84M 0.11%
141,237
+88,837
+170% +$4.2M

Similar funds

Candriam SCA's Q4 2018 Portfolio in Review

As of Q4 2018, Candriam SCA held 891 positions worth $6.51B, down 13% from $7.52B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Candriam SCA's Q4 2018 filing shows 87 new, 331 increased, 275 reduced and 84 closed positions. Its largest new stake was Azul: 501,000 shares worth $13.9M. The largest sale was TESARO, Inc., an estimated $32.8M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 33% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q4 2018 buy was Azul: 501,000 shares worth $13.9M.
  • Candriam SCA added most to Celgene Corp in Q4 2018, an estimated $60.9M increase.
  • Candriam SCA's biggest Q4 2018 reduction was TESARO, Inc., cutting an estimated $32.8M.
  • Candriam SCA fully exited Aetna Inc in Q4 2018, selling an estimated $20.2M.
  • Candriam SCA's ten largest holdings make up 20% of its $6.51B portfolio in Q4 2018.
  • Candriam SCA opened 87 new positions and closed 84 in Q4 2018.
  • Candriam SCA's portfolio value fell 13% quarter-over-quarter to $6.51B.

Based on Candriam SCA's 13F filing for Q4 2018, filed 14 Feb 2019.